Söndag 8 November | 00:26:16 Europe / Stockholm
Est. tid*
2026-08-11 - Kvartalsrapport 2026-Q2
2026-04-17 - X-dag bonusutdelning TECN 1.5
2026-04-17 - X-dag ordinarie utdelning TECN 1.50 CHF
2026-04-15 - Årsstämma
2026-03-16 - Bokslutskommuniké 2025
2025-08-12 - Kvartalsrapport 2025-Q2
2025-04-14 - X-dag bonusutdelning TECN 1.5
2025-04-14 - X-dag ordinarie utdelning TECN 1.50 CHF
2025-04-10 - Årsstämma
2025-03-12 - Bokslutskommuniké 2024
2024-08-13 - Kvartalsrapport 2024-Q2
2024-04-22 - X-dag bonusutdelning TECN 1.5
2024-04-22 - X-dag ordinarie utdelning TECN 1.50 CHF
2024-04-18 - Årsstämma
2024-03-12 - Bokslutskommuniké 2023
2023-08-15 - Kvartalsrapport 2023-Q2
2023-04-20 - X-dag bonusutdelning TECN 1.45
2023-04-20 - X-dag ordinarie utdelning TECN 1.45 CHF
2022-04-14 - X-dag ordinarie utdelning TECN 1.40 CHF
2021-04-15 - X-dag bonusutdelning TECN 1.15
2021-04-15 - X-dag ordinarie utdelning TECN 1.15 CHF
2020-04-09 - X-dag bonusutdelning TECN 1.1
2020-04-09 - X-dag ordinarie utdelning TECN 1.10 CHF
LandSchweiz
Lista86
Tecan Group specialiserar sig på tillverkning och försäljning av laboratorieinstrument och automatiseringssystem för bioteknik- och läkemedelsindustrin. Bolaget erbjuder lösningar för automatisering av biologiska och kemiska analysprocesser, inklusive prover, vätskehantering, DNA/RNA/protein-analys och sekvensering. Tecan betjänar forskare och läkemedelsföretag och är verksamma över hela världen. Huvudkontoret ligger i Männedorf, Schweiz.

All ägardata du vill ha finns i Holdings!

Tecan to present at upcoming Investor Conferences

2026-01-09 13:30:00

 Männedorf, Switzerland, January 9, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will attend and present at the following investor conferences in the upcoming week:

44th Annual J.P. Morgan Healthcare Conference, San Francisco, USA
Date: 14 January 2026
Presentation: 07:30am PST (4:30pm CET)
Presenter: Monica Manotas, CEO
Additional participants: Tania Micki, CFO & Martin Braendle, SVP, Corp. Comm. & Investor Relations
Webcast live under the "Investor Relations" tab of Tecan's website www.tecan.com.
A replay of the webcast will be available after the presentation and will remain available for 30 days.

Octavian Seminar 2026, Davos, Switzerland
Date: 16 January 2026
Participants: Monica Manotas, CEO
        Tania Micki, CFO
        Martin Braendle, SVP, Corp. Comm. & Investor Relations
Not webcasted.

About Tecan

Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
        
        
For further information:

Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com